Vice President, Early Clinical Development and Experimental Sciences, Rare Diseases, Regeneron Pharmaceuticals, Inc.
Dr. Mellis received medical scientist training at Washington University School of Medicine and postgraduate training in Internal Medicine and Rheumatology at Columbia University College of Physicians and Surgeons. He joined Pfizer Pharmaceuticals Group in 1990 with a focus on Zithromax® (azithromycin), including research on B. burgdorferi in collaboration with academic colleagues. Dr. Mellis joined Regeneron Pharmaceuticals in 2001, and led clinical development for ARCALYST® (rilonacept), a medication for an ultra-rare auto-inflammatory disease. He then led Regeneron’s translational and precision medicine initiatives across the general medicine portfolio. He is a co-founder of the Regeneron Genetics Center. Dr. Mellis is now leading an effort to optimize Regeneron’s development of new medications for patients with rare diseases.